Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 123

1.

Phase I/II Clinical Trial-Based Early Economic Evaluation of Acalabrutinib for Relapsed Chronic Lymphocytic Leukaemia.

Vreman RA, Geenen JW, Hövels AM, Goettsch WG, Leufkens HGM, Al MJ.

Appl Health Econ Health Policy. 2019 Jul 18. doi: 10.1007/s40258-019-00496-1. [Epub ahead of print]

PMID:
31317510
2.

First-line tyrosine kinase inhibitors in EGFR mutation-positive non-small-cell lung cancer: a network meta-analysis.

Holleman MS, van Tinteren H, Groen HJ, Al MJ, Uyl-de Groot CA.

Onco Targets Ther. 2019 Feb 20;12:1413-1421. doi: 10.2147/OTT.S189438. eCollection 2019. Review.

3.

Conceptual model for the health technology assessment of current and novel interventions in rheumatoid arthritis.

Alemao E, Al MJ, Boonen AA, Stevenson MD, Verstappen SMM, Michaud K, Weinblatt ME, Rutten-van Mölken MPMH.

PLoS One. 2018 Oct 5;13(10):e0205013. doi: 10.1371/journal.pone.0205013. eCollection 2018.

4.

An 18-year study of thyroid carcinoma in the western region of Saudi Arabia: a retrospective single-center study in a community hospital.

Aljabri KS, Bokhari SA, Al MA, Khan PM.

Ann Saudi Med. 2018 Sep-Oct;38(5):336-343. doi: 10.5144/0256-4947.2018.336.

5.

Ribociclib with an Aromatase Inhibitor for Previously Untreated, HR-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.

Büyükkaramikli NC, de Groot S, Riemsma R, Fayter D, Armstrong N, Portegijs P, Duffy S, Kleijnen J, Al MJ.

Pharmacoeconomics. 2019 Feb;37(2):141-153. doi: 10.1007/s40273-018-0708-4. Review.

6.

Identifying bioindicators across trait-taxon space for assessing water quality in marine environments.

Xu G, Zhong X, Al MA, Warren A, Xu H.

Mar Pollut Bull. 2018 Jun;131(Pt A):565-571. doi: 10.1016/j.marpolbul.2018.04.044. Epub 2018 May 1.

PMID:
29886983
7.

Cost-Effectiveness Analysis of Abatacept Compared with Adalimumab on Background Methotrexate in Biologic-Naive Adult Patients with Rheumatoid Arthritis and Poor Prognosis.

Alemao E, Johal S, Al MJ, Rutten-van Mölken M.

Value Health. 2018 Feb;21(2):193-202. doi: 10.1016/j.jval.2017.05.020. Epub 2017 Jul 1.

8.
9.

Early warning systems for the management of chronic heart failure: a systematic literature review of cost-effectiveness models.

Albuquerque De Almeida F, Al M, Koymans R, Caliskan K, Kerstens A, Severens JL.

Expert Rev Pharmacoecon Outcomes Res. 2018 Apr;18(2):161-175. doi: 10.1080/14737167.2018.1417841. Epub 2017 Dec 19. Review.

PMID:
29235882
10.

Pomalidomide with Dexamethasone for Treating Relapsed and Refractory Multiple Myeloma Previously Treated with Lenalidomide and Bortezomib: An Evidence Review Group Perspective of an NICE Single Technology Appraisal.

Büyükkaramikli NC, de Groot S, Fayter D, Wolff R, Armstrong N, Stirk L, Worthy G, Albuquerque de Almeida F, Kleijnen J, Al MJ.

Pharmacoeconomics. 2018 Feb;36(2):145-159. doi: 10.1007/s40273-017-0581-6. Review.

11.

A New Statistical Method to Determine the Degree of Validity of Health Economic Model Outcomes against Empirical Data.

Corro Ramos I, van Voorn GAK, Vemer P, Feenstra TL, Al MJ.

Value Health. 2017 Sep;20(8):1041-1047. doi: 10.1016/j.jval.2017.04.016. Epub 2017 May 29.

12.

Research Costs Investigated: A Study Into the Budgets of Dutch Publicly Funded Drug-Related Research.

van Asselt T, Ramaekers B, Corro Ramos I, Joore M, Al M, Lesman-Leegte I, Postma M, Vemer P, Feenstra T.

Pharmacoeconomics. 2018 Jan;36(1):105-113. doi: 10.1007/s40273-017-0572-7.

13.

Ramucirumab for Treating Advanced Gastric Cancer or Gastro-Oesophageal Junction Adenocarcinoma Previously Treated with Chemotherapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.

Büyükkaramikli NC, Blommestein HM, Riemsma R, Armstrong N, Clay FJ, Ross J, Worthy G, Severens J, Kleijnen J, Al MJ.

Pharmacoeconomics. 2017 Dec;35(12):1211-1221. doi: 10.1007/s40273-017-0528-y. Review.

14.

Faecal immunochemical tests to triage patients with lower abdominal symptoms for suspected colorectal cancer referrals in primary care: a systematic review and cost-effectiveness analysis.

Westwood M, Corro Ramos I, Lang S, Luyendijk M, Zaim R, Stirk L, Al M, Armstrong N, Kleijnen J.

Health Technol Assess. 2017 May;21(33):1-234. doi: 10.3310/hta21330. Review.

15.

Is survival after radical cystectomy for bladder cancer in Saudi patients different from that of Western patients?

Mokhtar A, Al MM, Al WM, Othman KA, Kattan SA, Al MF.

Ann Saudi Med. 2017 May-Jun;37(3):194-200. doi: 10.5144/0256-4947.2017.194.

16.

Mix and match. A simulation study on the impact of mixed-treatment comparison methods on health-economic outcomes.

Vemer P, Al MJ, Oppe M, Rutten-van Mölken MP.

PLoS One. 2017 Feb 2;12(2):e0171292. doi: 10.1371/journal.pone.0171292. eCollection 2017.

17.

Comparison of cardiovascular risk algorithms in patients with vs without rheumatoid arthritis and the role of C-reactive protein in predicting cardiovascular outcomes in rheumatoid arthritis.

Alemao E, Cawston H, Bourhis F, Al M, Rutten-van Molken M, Liao KP, Solomon DH.

Rheumatology (Oxford). 2017 May 1;56(5):777-786. doi: 10.1093/rheumatology/kew440.

PMID:
28087832
18.

IgA Complexes in Plasma and Synovial Fluid of Patients with Rheumatoid Arthritis Induce Neutrophil Extracellular Traps via FcαRI.

Aleyd E, Al M, Tuk CW, van der Laken CJ, van Egmond M.

J Immunol. 2016 Dec 15;197(12):4552-4559. Epub 2016 Nov 9.

19.

Cost-effectiveness analysis of new generation coronary CT scanners for difficult-to-image patients.

Burgers LT, Redekop WK, Al MJ, Lhachimi SK, Armstrong N, Walker S, Rothery C, Westwood M, Severens JL.

Eur J Health Econ. 2017 Jul;18(6):731-742. doi: 10.1007/s10198-016-0824-z. Epub 2016 Sep 20.

PMID:
27650359
20.

Cost Recommendation under Uncertainty in IQWiG's Efficiency Frontier Framework.

Corro Ramos I, Lhachimi SK, Gerber-Grote A, Al MJ.

Med Decis Making. 2017 Feb;37(2):162-172. doi: 10.1177/0272989X16636856. Epub 2016 Jul 10.

PMID:
27005521
21.

Integrated sensor-augmented pump therapy systems [the MiniMed® Paradigm™ Veo system and the Vibe™ and G4® PLATINUM CGM (continuous glucose monitoring) system] for managing blood glucose levels in type 1 diabetes: a systematic review and economic evaluation.

Riemsma R, Corro Ramos I, Birnie R, Büyükkaramikli N, Armstrong N, Ryder S, Duffy S, Worthy G, Al M, Severens J, Kleijnen J.

Health Technol Assess. 2016 Feb;20(17):v-xxxi, 1-251. doi: 10.3310/hta20170. Review.

22.

Cardiovascular risk factor management in patients with RA compared to matched non-RA patients.

Alemao E, Cawston H, Bourhis F, Al M, Rutten-van Mölken MP, Liao KP, Solomon DH.

Rheumatology (Oxford). 2016 May;55(5):809-16. doi: 10.1093/rheumatology/kev427. Epub 2015 Dec 24.

23.

AdViSHE: A Validation-Assessment Tool of Health-Economic Models for Decision Makers and Model Users.

Vemer P, Corro Ramos I, van Voorn GA, Al MJ, Feenstra TL.

Pharmacoeconomics. 2016 Apr;34(4):349-61. doi: 10.1007/s40273-015-0327-2.

24.

Use of Value of Information in Healthcare Decision Making: Exploring Multiple Perspectives.

Bindels J, Ramaekers B, Ramos IC, Mohseninejad L, Knies S, Grutters J, Postma M, Al M, Feenstra T, Joore M.

Pharmacoeconomics. 2016 Mar;34(3):315-22. doi: 10.1007/s40273-015-0346-z.

25.

Multifactorial resistance to aminopeptidase inhibitor prodrug CHR2863 in myeloid leukemia cells: down-regulation of carboxylesterase 1, drug sequestration in lipid droplets and pro-survival activation ERK/Akt/mTOR.

Verbrugge SE, Al M, Assaraf YG, Kammerer S, Chandrupatla DM, Honeywell R, Musters RP, Giovannetti E, O'Toole T, Scheffer GL, Krige D, de Gruijl TD, Niessen HW, Lems WF, Kramer PA, Scheper RJ, Cloos J, Ossenkoppele GJ, Peters GJ, Jansen G.

Oncotarget. 2016 Feb 2;7(5):5240-57. doi: 10.18632/oncotarget.6169.

26.

Cost-Effectiveness of Including a Nurse Specialist in the Treatment of Urinary Incontinence in Primary Care in the Netherlands.

Holtzer-Goor KM, Gaultney JG, van Houten P, Wagg AS, Huygens SA, Nielen MM, Albers-Heitner CP, Redekop WK, Rutten-van Mölken MP, Al MJ.

PLoS One. 2015 Oct 1;10(10):e0138225. doi: 10.1371/journal.pone.0138225. eCollection 2015.

27.

The Missing Stakeholder Group: Why Patients Should be Involved in Health Economic Modelling.

van Voorn GA, Vemer P, Hamerlijnck D, Ramos IC, Teunissen GJ, Al M, Feenstra TL.

Appl Health Econ Health Policy. 2016 Apr;14(2):129-33. doi: 10.1007/s40258-015-0200-7.

28.

Cost-effectiveness of adding rituximab to fludarabine and cyclophosphamide for treatment of chronic lymphocytic leukemia in Ukraine.

Mandrik O, Corro Ramos I, Knies S, Al M, Severens JL.

Cancer Manag Res. 2015 Aug 25;7:279-89. doi: 10.2147/CMAR.S79258. eCollection 2015.

29.

Lenalidomide for the Treatment of Low- or Intermediate-1-Risk Myelodysplastic Syndromes Associated with Deletion 5q Cytogenetic Abnormality: An Evidence Review of the NICE Submission from Celgene.

Blommestein HM, Armstrong N, Ryder S, Deshpande S, Worthy G, Noake C, Riemsma R, Kleijnen J, Severens JL, Al MJ.

Pharmacoeconomics. 2016 Jan;34(1):23-31. doi: 10.1007/s40273-015-0318-3.

30.

Effects of Achieving Target Measures in Rheumatoid Arthritis on Functional Status, Quality of Life, and Resource Utilization: Analysis of Clinical Practice Data.

Alemao E, Joo S, Kawabata H, Al MJ, Allison PD, Rutten-van Mölken MP, Frits ML, Iannaccone CK, Shadick NA, Weinblatt ME.

Arthritis Care Res (Hoboken). 2016 Mar;68(3):308-17. doi: 10.1002/acr.22678.

31.

Viscoelastic point-of-care testing to assist with the diagnosis, management and monitoring of haemostasis: a systematic review and cost-effectiveness analysis.

Whiting P, Al M, Westwood M, Ramos IC, Ryder S, Armstrong N, Misso K, Ross J, Severens J, Kleijnen J.

Health Technol Assess. 2015 Jul;19(58):1-228, v-vi. doi: 10.3310/hta19580. Review.

32.

Determining the impact of modeling additional sources of uncertainty in value-of-information analysis.

Ramos IC, P M H M, Mölken RV, Al MJ.

Value Health. 2015 Jan;18(1):100-9. doi: 10.1016/j.jval.2014.09.003. Epub 2014 Dec 10.

33.

The use of fenestrated and branched endovascular aneurysm repair for juxtarenal and thoracoabdominal aneurysms: a systematic review and cost-effectiveness analysis.

Armstrong N, Burgers L, Deshpande S, Al M, Riemsma R, Vallabhaneni SR, Holt P, Severens J, Kleijnen J.

Health Technol Assess. 2014 Dec;18(70):1-66. doi: 10.3310/hta18700. Review.

34.

Advishe: a New Tool to Report Validation of Health-Economic Decision Models.

Vemer P, Corro Ramos I, Van Voorn G, Al MJ, Feenstra TL.

Value Health. 2014 Nov;17(7):A556-7. doi: 10.1016/j.jval.2014.08.1831. Epub 2014 Oct 26. No abstract available.

35.

Treating to the Target of Das28 < 2.6 in Rheumatoid Arthritis: the Impact of Efficacy on Cost Effectiveness.

Alemao E, Johal S, Al MJ, Rutten-van MM.

Value Health. 2014 Nov;17(7):A378-9. doi: 10.1016/j.jval.2014.08.2605. Epub 2014 Oct 26. No abstract available.

37.

Turner Syndrome Genotype and phenotype and their effect on presenting features and timing of Diagnosis.

Al Alwan I, M K, Amir 1st, G N, A O, L B, M AD, M B.

Int J Health Sci (Qassim). 2014 Apr;8(2):195-202.

38.

Liver transplantation at KFSHRC: achievement and challenges.

Al MI, Abaalkhail FA, Bahili HA, Abdo AH, Elsiesy HA, Al MS, El Sheikh YM, Hegab BS, Kamel YM, AlGoufi TT, Hasssan HH, Burdelski MM, Al MA, Abdelfattah MR, Attallah KM, Mahmood TZ, Saleh YZ, Eldeen FZ, Broering DC.

Ann Saudi Med. 2014 Mar-Apr;34(2):103-6. doi: 10.5144/0256-4947.2014.10.

39.

[Review of multicentre clinical trials is simplified; more trial centres are approved in the first assessment round].

Heringa JW, Al MD, Koëter GH.

Ned Tijdschr Geneeskd. 2014;158:A7558. Dutch.

PMID:
24846116
40.

Ivacaftor for the treatment of patients with cystic fibrosis and the G551D mutation: a systematic review and cost-effectiveness analysis.

Whiting P, Al M, Burgers L, Westwood M, Ryder S, Hoogendoorn M, Armstrong N, Allen A, Severens H, Kleijnen J.

Health Technol Assess. 2014 Mar;18(18):1-106. doi: 10.3310/hta18180. Review.

41.

SeHCAT [tauroselcholic (selenium-75) acid] for the investigation of bile acid malabsorption and measurement of bile acid pool loss: a systematic review and cost-effectiveness analysis.

Riemsma R, Al M, Corro Ramos I, Deshpande SN, Armstrong N, Lee YC, Ryder S, Noake C, Krol M, Oppe M, Kleijnen J, Severens H.

Health Technol Assess. 2013 Dec;17(61):1-236. doi: 10.3310/hta17610. Review.

42.

Economic evaluation alongside a single RCT of an integrative psychotherapeutic nursing home programme.

Hakkaart-van Roijen L, Bakker TJ, Al M, van der Lee J, Duivenvoorden HJ, Ribbe MW, Huijsman R.

BMC Health Serv Res. 2013 Sep 30;13:370. doi: 10.1186/1472-6963-13-370.

43.

Improving model validation in health technology assessment: comments on guidelines of the ISPOR-SMDM modeling good research practices task force.

Vemer P, van Voom GA, Ramos IC, Krabbe PF, Al MJ, Feenstra TL.

Value Health. 2013 Sep-Oct;16(6):1106-7. doi: 10.1016/j.jval.2013.06.015. No abstract available. Erratum in: Value Health. 2013 Dec;16(8):1174. Ramos, Corro [corrected to Ramos, Isaac Corro]; Krabbe, P F M [corrected to Krabbe, Paul F M]; Al, M J [corrected to Al, Maiwenn J]; Feenstra, T L [corrected to Feenstra, Talitha L].

44.

A choice that matters? Smulation study on the impact of direct meta-analysis methods on health economic outcomes.

Vemer P, Al MJ, Oppe M, Rutten-van Mölken MP.

Pharmacoeconomics. 2013 Aug;31(8):719-30. doi: 10.1007/s40273-013-0067-0.

PMID:
23736971
45.

Real-life compliance and persistence among users of subcutaneous and sublingual allergen immunotherapy.

Kiel MA, Röder E, Gerth van Wijk R, Al MJ, Hop WC, Rutten-van Mölken MP.

J Allergy Clin Immunol. 2013 Aug;132(2):353-60.e2. doi: 10.1016/j.jaci.2013.03.013. Epub 2013 May 4.

PMID:
23651609
46.

Continuous versus intermittent data collection of health care utilization.

Hendriks MR, Al MJ, Bleijlevens MH, van Haastregt JC, Crebolder HF, van Eijk JT, Evers SM.

Med Decis Making. 2013 Nov;33(8):998-1008. doi: 10.1177/0272989X13482045. Epub 2013 Mar 27.

PMID:
23535608
47.

A systematic review and economic evaluation of new-generation computed tomography scanners for imaging in coronary artery disease and congenital heart disease: Somatom Definition Flash, Aquilion ONE, Brilliance iCT and Discovery CT750 HD.

Westwood M, Al M, Burgers L, Redekop K, Lhachimi S, Armstrong N, Raatz H, Misso K, Severens J, Kleijnen J.

Health Technol Assess. 2013;17(9):1-243. doi: 10.3310/hta17090. Review.

48.

Cost-effectiveness acceptability curves revisited.

Al MJ.

Pharmacoeconomics. 2013 Feb;31(2):93-100. doi: 10.1007/s40273-012-0011-8.

PMID:
23329426
49.

Overcoming bortezomib resistance in human B cells by anti-CD20/rituximab-mediated complement-dependent cytotoxicity and epoxyketone-based irreversible proteasome inhibitors.

Verbrugge SE, Al M, Assaraf YG, Niewerth D, van Meerloo J, Cloos J, van der Veer M, Scheffer GL, Peters GJ, Chan ET, Anderl JL, Kirk CJ, Zweegman S, Dijkmans BA, Lems WF, Scheper RJ, de Gruijl TD, Jansen G.

Exp Hematol Oncol. 2013 Jan 10;2(1):2. doi: 10.1186/2162-3619-2-2.

50.

The role of value-of-information analysis in a health care research priority setting: a theoretical case study.

Corro Ramos I, Rutten-van Mölken MP, Al MJ.

Med Decis Making. 2013 May;33(4):472-89. doi: 10.1177/0272989X12468616. Epub 2012 Dec 28.

PMID:
23275451

Supplemental Content

Loading ...
Support Center